Pharmacology, Toxicology and Pharmaceutical Science
Pralmorelin
100%
Growth Hormone Releasing Factor
96%
Growth Hormone
90%
Liraglutide
64%
Drug
49%
Non Insulin Dependent Diabetes Mellitus
30%
Clinical Trial
21%
Rosiglitazone
21%
Pioglitazone
21%
Troglitazone
21%
Diabetes Mellitus
13%
Glucose
10%
Liver Injury
10%
Low Density Lipoprotein Cholesterol
10%
Cardiovascular Risk
10%
Insulin Sensitizing Agent
10%
Dyslipidemia
10%
Metabolic Syndrome X
10%
Low Density Lipoprotein
10%
Peroxisome Proliferator Activated Receptor
10%
Insulin
10%
Atherosclerosis
10%
Liver Failure
10%
Insulin Resistance
10%
Receptor
10%
Adverse Event
10%
Coronary Artery Disease
10%
Obesity
9%
Human
6%
Medicine and Dentistry
Thiazolidinedione
64%
Chemotherapeutic Agent
43%
Drug
43%
Maturity Onset Diabetes of the Young
21%
Troglitazone
21%
Rosiglitazone
21%
Pioglitazone
21%
Cardiovascular System
10%
Insulin Sensitizing Agent
10%
Metabolic Syndrome
10%
Liver Failure
10%
Cardiovascular Disease
10%
Low-Density Lipoprotein
10%
Cardiovascular Risk
10%
Peroxisome Proliferator Activated Receptor
10%
Liver Injury
10%
Dyslipidemia
10%
Coronary Artery Disease
10%
Artery Intima
10%
Receptor
10%
Intima-Media Thickness
10%
Fibrinolysis
10%
Blood Pressure
10%
Adverse Event
10%
Glucose
10%
Carotid Artery
10%
In Vitro
10%
Insulin Resistance
10%
Diabetes Mellitus
10%
Aptitude
10%
Mechanism of Action
10%
Therapeutic Procedure
10%
Low Density Lipoprotein Cholesterol
10%
Atherosclerosis
10%
Inpatient
10%
Plasma
10%
Patient with Type 2 Diabetes
10%
Nursing and Health Professions
Growth Hormone
64%
Liraglutide
64%
Placebo
49%
Growth Hormone Releasing Factor
32%
Dose
18%
Body Weight Loss
15%
Woman
12%
Man
12%
Non Insulin Dependent Diabetes Mellitus
9%
Obesity
9%
Weight
9%
Adult
6%
Drug
6%
